Volume 26, No 7, Jul 2016

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 26 Issue 7, July 2016: 850-853

LETTERS TO THE EDITOR

Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer

Feifei Luo^1,2, Jiawen Qian², Jiao Yang², Yuting Deng², Xiujuan Zheng², Jie Liu^1,2 and Yiwei Chu^1,2

¹Department of Digestive Diseases, Huashan Hospital and Department of Immunology of School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
²Biotherapy Research Center, Fudan University, Shanghai 200032, China Correspondence: Jie Liu, E-mail: jieliu@fudan.edu.cn; Yiwei Chu,(yiweichu@fudan.edu.cn)

Genetically engineered T cell therapy is a promising new strategy to combat cancer. The chimeric antigen receptor-expressing T cell (CART) approach has achieved success in clinical trials of patients with non-solid tumors1,2. Some limitations nevertheless have emerged. Among them are restriction of the CARs to the cell surface and the risks associated with retroviral integration in the genome3,4.

10.1038/cr.2016.81

FULL TEXT | PDF

Browse 1692